According to a new study published online in the Journal of the National Cancer Institute, researchers from the American Cancer Society and Massachusetts General Hospital Cancer Center in Boston have found that the addition of radiotherapy to hormonal therapy may improve survival in men with node-positive prostate cancer who are at significant risk of cancer-related death.
The study showed that approximately half of patients with node-positive prostate cancer in the United States who had not received combined radiation therapy and hormonal therapy and were therefore not receiving the treatment that could best inhibit tumor growth and improve survival.
"Our analysis of a large national database revealed that adding radiation therapy to androgen-deprivation therapy decreased the risk of death in these patients by 50 percent over five years," says Jason Efstathiou, MD, DPhil, of the MGH Cancer Center and Department of Radiation Oncology, senior author of the study.
Researchers found that more aggressive local management of prostate cancer that is limited to the pelvis can result in more durable disease control, limit cancer metastasis, and potentially cure some patients.
A new study finds that men with prostate cancer that has spread to nearby lymph nodes, who have a significant risk of dying from the disease, can benefit from the addition of radiation therapy to treatments that block the effects of testosterone.